Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lapatinib + sorafenib
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor, and sorafenib, a multi-kinase inhibitor. This combination targets multiple cancer pathways simultaneously, showing synergistic effects in killing tumor cells, particularly in CNS tumors. Phase I trials have demonstrated promising clinical activity with a disease control rate of 63% in advanced refractory solid tumors, though long-term tolerability remains challenging.
02
Targets
RAF1 (c-Raf-1 (Y340D/Y341D))HTR2A (5-hydroxytryptamine receptor 2A)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)ERBB2 (Erb-b2 receptor tyrosine kinase 2)BRAF (B-Raf proto-oncogene, serine/threonine kinase)EGFR T790M (Epidermal growth factor receptor T790M mutant)VEGFR4 (Vascular endothelial growth factor Receptor-3)VEGFR-1 (Vascular endothelial growth factor receptor 1)FLT3 (Fms related receptor tyrosine kinase 3)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on lapatinib + sorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lapatinib + sorafenib.